The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Morgan Stanley analyst Craig Hettenbach downgraded Hims & Hers to Equal Weight from Overweight with a price target of $60, up from $42. The ...

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...

The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.

Yeezy isn’t the only company being called out for its “bait-and-switch” Super Bowl commercial, a Californian company called ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without ...

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...

Hims & Hers (HIMS) stock dips as Morgan Stanley downgrades the telehealth firm citing its recent rally in share price. Read more here.

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.